Nanoparticles have been heralded as a potentially “disruptive technology” in biomedicine, and as a changing platform that could replace conventional technologies, both as drug delivery vehicles and diagnostic tools to help discover and treat disease.
While obstructive sleep apnea syndrome (OSAS) is a relatively common condition, affecting about 2 to 4 percent of young children, the scientific community is just opening its eyes to pediatric sleep disorders. Little is known, for example, about the characteristics that increase OSAS severity in children.
Imagine facing a devastating medical problem, but when you searched for a diagnosis, even the experts had no answers because your condition was so rare. In the U.S., a disease is considered rare if it affects fewer than 200,000 people.
In a move designed to facilitate investigations across the organization, The Children’s Hospital of Philadelphia Research Institute recently created a new office that consolidates clinical trial support, IND/IDE assistance, and general research support in one office.